Trial Profile
A Phase Ib, Multi-center, Open, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Ningetinib (CT053PTSA) in Relapsed / Refractory Acute Myeloid Leukemia (AML)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ningetinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Sunshine Lake Pharma
- 22 Mar 2021 Status changed from recruiting to discontinued.
- 02 Jan 2019 Status changed from not yet recruiting to recruiting.
- 28 Apr 2017 New trial record